Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer

Area of Science:

• Oncology
• Molecular Pathology
• Cancer Research

Background:

• Transitional cell carcinoma (TCC) is the most common type of bladder cancer.
• The c-erbB-2 oncoprotein is implicated in various cancers, but its role in TCC prognosis is unclear.

Purpose of the Study:

• To evaluate c-erbB-2 oncoprotein overexpression in TCC.
• To correlate c-erbB-2 expression with histopathological features and clinical outcomes.
• To determine the prognostic significance of c-erbB-2 in TCC.

Main Methods:

• Immunohistochemical staining of paraffin-embedded TCC tissues (n=249) for c-erbB-2 oncoprotein.
• Correlation analysis with histopathological parameters (T-category, WHO grade) and clinical data (lymph node involvement, metastasis).
• Assessment of DNA ploidy and S-phase fraction using flow cytometry; evaluation of prognostic value through survival analysis.

Main Results:

• 39% of TCCs showed c-erbB-2 positivity, with 12.5% exhibiting moderate/heavy staining.
• Overexpression correlated with pelvic lymph node involvement (P=0.0355), distant metastasis (P=0.0058), high WHO grade (P=0.0033), DNA aneuploidy (P=0.0061), high S-phase fraction (P=0.042), and nuclear factors.
• High c-erbB-2 expression was associated with tetraploidy (P<0.0001); however, it lacked independent prognostic value in multivariate analysis.

Conclusions:

• C-erbB-2 oncoprotein overexpression is frequent in TCC and associated with adverse prognostic factors.
• Immunohistochemical detection of c-erbB-2 overexpression does not provide independent prognostic information beyond established predictors in TCC.
• Further research may explore targeted therapies based on c-erbB-2 status in specific TCC subsets.